Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

Opinion
Video

Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.

Related Videos
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"